Muscle mass is an important risk factor for poor outcomes in COPD. The sarcopenia index (SI) (serum creatinine value/cystatin C value) X100 is a novel blood test to approximate muscle mass. The objective of this study is to analyze the correlation between Sarcopenia index (SI) and different COPD Outcomes.
SI was calculated in 56 COPD patients from january 2016 to january 2017. Body Mass Index (BMI), Fat free Mass Index (FFMI), FEV1, Dyspnoea (mMRC), number of exacerbations in the previous year, number of exacerbations needing hospitalization, COPD Assessment Test (CAT) score and Six minute Walking test (6MWT) distance (m) were measured in these patients.
Mean+/-Standard deviation age, BMI, FEV1, CAT, FFMI and 6MWT were respectively 66,8+/-7,3, 28,1+/-5,6 kg/m2, 53,4+/-17% 14+/-8 points, 18,7+/-2,4 Kg/m2 and 400+/-119. 75% were men. Mean SI was 89+/-20,5. SI correlates positively with FEV1 Pearson 0,495 p<0,001, 6MWT Pearson 0,603 (p<0,001), and negatively with CAT Pearson-0,387 (p=0,009), mMRC Spearman -0,379 (p=0,004), number of exacerbations in the previous 12 months Spearman -0,383 p=0,004 and hospitalization in the previous 12 months Spearman -0,531 (p<0,001). Curiously, no statistically significant correlations were found with FFMI (p=0,148) or BMI (p=0,425).
In conclusion SI is a promising tool for COPD that correlates with several relevant clinical outcomes.
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA722.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).